White Paper

Rare And Orphan Diseases: Choosing A Path To Regulatory Approval And Market Success

Source: Advarra

By Sharon Ayd, Vice President, Principal Regulatory Center of Excellence, Advarra


Medical science has identified about 7,000 rare or “orphan” diseases. These conditions only affect a small percentage of the population: in the United States, we consider a rare disease as one affecting fewer than 200,000 people.

Historically, the small number of affected persons has meant a lack of market demand to encourage industry investment toward treatment. As a result, drug makers have typically paid less attention to rare diseases. Despite increased support from governments, regulators, and public opinion, significant challenges still continue for sponsors willing to bring these drugs to market. This white paper examines those challenges within the U.S. system and provides some guidance to sponsors on meeting them.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader